Health
FDA approves first treatment for a rare genetic disorder – News-Medical.Net
Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder.
Reviewed by Emily Henderson, B.Sc.Nov 23 2020
Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of experts and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.
The approval of Oxlumo represents a great triumph of community involvement to address a rare disease. It is a result of input…
-
Noosa News24 hours agoSurfer attacked by Great White shark off northern NSW coast
-
Noosa News22 hours agoUrgent warning to locals as multiple crews battle major industrial fire at Rocklea in Brisbane’s south
-
General24 hours agoCronulla Sharks captain Cameron McInnes to miss remainder of 2025 with second ACL rupture
-
Noosa News24 hours ago12-year-old charged with attempted murder over alleged stabbing at Augustine Heights in Ipswich